DAIC

FEBRUARY 29, 2024

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Cardiology Update

APRIL 9, 2024

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. These patients were identified to have non-flow-limiting vulnerable coronary plaques through intracoronary imaging.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF).

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Key Takeaways: Greater Weight Loss, Greater Benefit : Achieving 2-5% weight loss yields metabolic improvements, while over 15% weight loss significantly reduces obesity-related complications like hypertension, NAFLD, and heart failure with preserved ejection fraction (HFpEF).

CME 103

CME Obesity Heart Failure Biomarkers 103